Justdapa-Trio 10/100/500 Tablet ER: Comprehensive Diabetes Management

Justdapa-Trio 10/100/500 Tablet ER is a once-daily extended-release tablet formulation designed for the management of Type 2 diabetes. This combination therapy blends the following:

* Dapagliflozin (10mg): A sodium-glucose cotransporter-2 inhibitor, helping to lower blood glucose levels by preventing sugar reabsorption in the kidneys.
* Metformin (500mg): A metformin, an initial choice for Type 2 diabetes treatment, assists in lowering blood sugar through its effect on glucose production within the liver and uptake in muscle cells.
* Sitagliptin (100mg): A dipeptidyl peptidase-4 inhibitor that enhances insulin secretion from pancreatic beta cells and reduces glucagon release, thereby lowering blood glucose levels.

This unique formulation provides a comprehensive approach to managing Type 2 diabetes by addressing different aspects of the disease's pathophysiology. It is crucial for individuals with Type 2 diabetes who are looking for an effective, once-daily solution to improve their glycemic control.

Please note: This information is not a substitute for professional medical advice. Consult your healthcare provider before starting any new medication.